| Literature DB >> 33953580 |
Miroslaw Janczura1, Rafal Rosa2, Jerzy Dropinski3, Anna Gielicz3, Andrzej Stanisz4, Katarzyna Kotula-Horowitz5, Teresa Domagala6.
Abstract
PURPOSE: Associations between perceived stress and oxidative stress marker and metabolic syndrome (MetS) components were investigated in a cohort of police officers.Entities:
Keywords: hypertension; metabolic syndrome; obesity; oxidative stress; perceived stress; physical activity
Year: 2021 PMID: 33953580 PMCID: PMC8090790 DOI: 10.2147/DMSO.S298596
Source DB: PubMed Journal: Diabetes Metab Syndr Obes ISSN: 1178-7007 Impact factor: 3.168
Characteristics of the Study Subjects, as Stratified by MetS Status
| Variable | MetS | Non-MetS | P-value* |
|---|---|---|---|
| N (women) | 104 (3) | 129 (16) | |
| Age; years | 41.00 (38.00–46.00) | 39.00 (36.00–42.00) | 0.0001 |
| Education Higher; n (%) | 47 (45.19) | 89 (69.00) | 0.0002 |
| FRS | 7.75 (4.20–10.60) | 2.60 (1.00–5.00) | <0.0001 |
| BMI; kg/m | 32.00 (29.47–34.31) | 27.69 (25.26–29.86) | <0.0001 |
| Overweight, n (%) | 32 (30.77) | 71 (55.04) | 0.0002 |
| Obesity; n (%) | 73 (70.19) | 27 (20.93) | <0.0001 |
| Hypertension; n (%) | 72 (69.23) | 39 (30.23) | <0.0001 |
| Stable CHD, n (%) | 12 (11.54) | 5 (3.87) | 0.02 |
| Coronary plaque; n (%)** | 28 (37.84) | 14 (18.92) | 0.007 |
| SBP; mm Hg | 140.00 (135.00–147.50) | 120.00(110.00–135.00) | <0.0001 |
| DBP; mm Hg | 90.00 (80.00–90.00) | 80.00 (80.00–85.00) | <0.0001 |
| cIMT; mm | 0.57 (0.525–0.63) | 0.53 (0.47–0.58) | 0.0001 |
| Current smoking; n (%) | 40 (38.46) | 35 (27.13) | 0.10 |
| LDL cholesterol; mmol/L | 3.24 (2.73–3.86) | 2.99 (2.44–3.59) | 0.03 |
| HDL cholesterol; mmol/L | 1.10 (0.90–1.27) | 1.30 (1.12–1.49) | <0.0001 |
| Triglycerides, mmol/L | 2.54 (1.98–3.16) | 1.21 (0.91–1.56) | <0.0001 |
| Glucose; mmol/L | 5.50 (5.10–5.80) | 5.10 (4.80–5.30) | <0.0001 |
| Insulin; µIU/mL | 22.54 (15.84–29.40) | 12.98 (9.02–19.16) | <0.0001 |
| HOMA-IR | 2.90 (2.10–3.77) | 1.68 (1.19–2.44) | <0.0001 |
| CRP; mg/L | 1.36 (0.78–2.40) | 0.88 (0.42–2.15) | 0.0005 |
| 8-isoPGF2a; pg/mL | 8.32 (5.93–10.20) | 6.37 (4.60–8.47) | 0.0001 |
| Fibrinogen; g/L | 3.29 (2.90–3.80) | 3.24 (2.80–3.64) | 0.22 |
| PSS score | 18.00 (15.00–22.00) | 16.00 (12.00–20.00) | 0.02 |
| Medications, n (%) | |||
| Aspirin | 6 (5.77) | 3 (2.32) | 0.18 |
| ACEI/ARB | 23 (22.11) | 15 (11.63) | 0.03 |
| β-blocker | 28 (26.92) | 12 (9.30) | 0.0006 |
| Ca-blocker | 11 (10.57) | 2 (1.55) | 0.003 |
| Diuretics | 17 (16.35) | 11 (8.53) | 0.08 |
| Lipid-lowering agents | 7 (6.67) | 4 (3.10) | 0.22 |
Notes: Data are expressed as no. (%), or median (interquartile range). *Chi-squared for categorical and Mann–Whitney U-test for continuous variables were used. **n(%) subjects who underwent computed tomography coronary angiography.
Abbreviations: MetS, metabolic syndrome; FRS, Framingham Risk Score (10-year risk of developing coronary heart disease); CHD, coronary heart disease; BMI, body mass index; cIMT, carotid intima-media thickness; LDL, low-density lipoprotein; HDL, high-density lipoprotein; CRP, C-reactive protein; SBP (DBP), systolic (diastolic) blood pressure; HOMA-IR, the homeostasis model assessment of insulin resistance; 8-iso-PGF2α, 8-iso-prostaglandin F2α; PSS, perceived stress scale; ACEI/ARB, angiotensin-converting enzyme inhibitor/angiotensin receptor blocker.
Prevalence of Metabolic Syndrome Components
| Variable | All Subjects | Number of Metabolic Syndrome Components | ||||
|---|---|---|---|---|---|---|
| 0 | 1 | 2 | 3 | ≥4 | ||
| Subjects | 233 (100) | 33 (14.16) | 39 (16.74) | 57 (24.46) | 58 (24.90) | 46 (19.74) |
| Age; years* | 40.00 | 38.00 | 40.00 | 40.50 | 41.00 | 42.00 |
| Waist circumference ≥ 94 cm in men, ≥ 80 cm in women | 166 (70.94) | – | 18 (46.15) | 44 (77.19) | 58 (100.00) | 46 (100) |
| Blood pressure: systolic ≥130 mm Hg, diastolic ≥85 mm Hg, or antihypertensive medication use | 139 (59.66) | – | 10 (25.64) | 42 (75.0) | 47 (81.03) | 40 (86.96) |
| Triglycerides ≥ 1.7 mmol/L (150 mg/dL) | 111 (47.64) | – | 6 (15.38) | 18 (31.57) | 43 (74.13) | 45 (97.82) |
| HDL cholesterol | 57 (24.46) | – | 2 (5.13) | 8 (14.28) | 15 (25.86) | 32 (69.56) |
| Fasting glucose ≥5.6 mmol/L (100 mg/dL) | 52 (22.32) | – | 3 (6.79) | 4 (7.14) | 12 (20.68) | 33 (71.74) |
Note: Data are presented as n (%) or *as median (interquartile range).
Clinical Variables and Plasma 8-Iso-PGF2α Levels, and Physical Activity in the Select Domains, as Stratified by Metabolic Syndrome Components Status
| Variable | All subjects | Number of Metabolic Syndrome Components | P | ||||
|---|---|---|---|---|---|---|---|
| 0 | 1 | 2 | 3 | ≥4 | |||
| Subjects; n (%) | 233 (100) | 33 (14.16) | 39 (16.74) | 57 (24.46) | 58 (24.90) | 46 (19.74) | |
| Obesity; n(%) | 100 (42.92) | 0 (0) | 7 (17.95) | 20 (35.09) | 35 (60.34) | 38 (82.61) | <0.001* |
| Hypertension; n (%) | 111 (47.64) | 0 (0) | 5 (12.82) | 34 (59.65) | 35 (60.34) | 37 (80.43) | <0.001* |
| Coronary plaque; n (%)*** | 42 (27.63) | 0 (0) | 4 (17.39) | 10 (25.64) | 12 (30.00) | 16 (45.71) | 0.001* |
| cIMT; mm | 0.550 | 0.525 | 0.550 | 0.545 | 0.555 | 0.577 | 0.005** |
| Plasma 8-iso-PGF2α; pg/mL | 7.14 | 6.27 | 5.49 | 6.66 | 8.80 | 8.43 | 0.003** |
| Physical activity (Corrected MET-minutes/week/kg of body weight) | |||||||
| Leisure time | 14.51 | 23.92 | 38.15 | 18.67 | 9.84 | 6.23 | 0.02** |
| Total walking | 44.41 | 45.92 | 88.98 | 32.46 | 38.92 | 31.04 | 0.04** |
| Total physical activity | 125.53 | 171.35 | 158.69 | 112.73 | 125.50 | 116.15 | 0.41** |
Notes: Data are presented as n (%) or as median (interquartile range). *Chi-squared test, **Kruskal-Wallis test. ***n(%) subjects who underwent computed tomography coronary angiography; hypertension was diagnosed, if systolic/diastolic blood pressure was ≥140/≥90 mm Hg, or the previously diagnosed hypertension was currently treated with anti-hypertensive medications; obesity was defined as BMI>30.0 kg/m2.
Abbreviations: cIMT, carotid intima-media thickness; 8-iso-PGF2α, 8-iso-prostaglandin F2α; MET, metabolic equivalent of task.
Associations Between Respective Variables in Univariate Linear Analyses, for All Study Subjects
| Independent | Dependent Variable | |||||||
|---|---|---|---|---|---|---|---|---|
| Waist Circumference | HDL Cholesterol | Triglycerides | Glucose | HOMA-IR | SBP | DBP | 8-Iso-PGF2α | |
| PSS | 0.326* | −0.003 | 0.015 | 0.0009 | 0.007 | 0.622* | 0.369* | 0.127* |
| Age | 0.686 | −0.002 | 0.046* | 0.044*** | 0.010 | 0.687** | 0.372** | 0.020 |
| BMI | 2.44*** | −0.030*** | 0.137*** | 0.078*** | 0.169*** | 1.341*** | 0.899*** | 0.128* |
| LDL cholesterol | 0.0001 | −0.176 | 0.061 | −0.069 | 0.137 | 2.604 | 1.784 | 0.489 |
| Fibrinogen | 0.009* | −0.032 | 0.083 | −0.033 | 0.105 | 3.496* | 2.002* | 0.725* |
| CRP | 1.690** | −0.010 | 0.025 | 0.030 | 0.077* | 1.542* | 1.123** | 0.242* |
| Waist circumference | - | −0.011*** | 0.057*** | 0.026*** | 0.061*** | 0.549*** | 0.365*** | 0.047* |
| HDL cholesterol | - | - | −0.093*** | −0.282* | −1.011*** | 4.185 | 1.409 | −0.491 |
| Triglycerides | - | - | - | 0.047 | 0.193*** | 2.304* | 0.865 | 0.226 |
| Glucose | - | - | - | - | - | 3.602* | 2.835* | 0.422 |
| HOMA-IR | - | - | - | - | - | 4.122*** | 1.908** | 0.468* |
| 8-iso-PGF2α | - | - | - | - | - | 0.872* | 0.721* | - |
| Leisure time | −0.074* | 0.0005 | −0.01* | −0.0002 | −0.004 | −0.073 | −0.026 | −0.006 |
| Total walking | −0.032* | 0.0007 | −0.004* | −0.0001 | −0.002 | −0.019 | −0.007 | −0.0005 |
| Total physical activity | −0.013* | 0.0003 | −0.002* | −0.000005 | −0.001 | −0.009 | −0.001 | 0.001 |
Note: Data are presented as unstandardized coefficient (95% CI).
Abbreviations: CI, confidence interval; 8-iso-PGF2α, 8-iso-prostaglandin F2α; S(D)BP, systolic (diastolic) blood pressure; CRP, C-reactive protein; HOMA-IR, homeostasis model assessment of insulin resistance; BMI, body mass index; PSS, perceived stress scale. *p<0.05, **p<0.001, ***p<0.0001.
Results of Linear Regression Regarding the Effect of Select Variables on Plasma 8-Iso-PGF2α, as Stratified by Gender
| Independent Variable | Men | Women |
|---|---|---|
| B (95% CI), p-value | B (95% CI), p-value | |
| Waist circumference | 0.056 (0.012, 0.101), 0.01 | −0.082 (−0.228, 0.063), 0.25 |
| Triglycerides | 0.226 (−0.051, 0.505), 0.10 | 2.184 (−0.398, 4.766), 0.09 |
| HDL cholesterol | −0.469 (−1.081, 0.863), 0.48 | −0.595 (−4.051, 2.861), 0.72 |
| Glucose | 0.289 (−0.548, 1.126), 0.49 | −1.649 (−4.913, 0.911), 0.19 |
| SBP | 0.030 (0.004, 0.056), 0.01 | −0.005 (−0.107, 0.096), 0.91 |
| PSS score | 0.122 (0.029, 0.215), 0.01 | 0.216 (−0.238, 0.671), 0.31 |
Notes: Upper line – univariate model; lower line – multivariate model, adjusted for age, and current smoking. In regression models, 8-iso-PGF2α was a dependent variable.
Abbreviations: B, unstandardized coefficient; CI, confidence interval; SBP, systolic blood pressure; 8-iso-PGF2α, 8-iso-prostaglandin F2α, PSS, perceived stress scale.
Results of Logistic Regression Regarding the Prevalence of Hypertension, as Stratified by Gender
| Independent Variable | Men | Women |
|---|---|---|
| OR (95% CI), p-value | OR (95% CI), p-value | |
| Waist circumference | 1.900 (1.054–1.127), <0.0001 | 0,976 (0.854–1.114), 0.69 |
| Triglycerides | 1.298 (1.031–1.611), 0.02 | 0.863 (0.081–9.254), 0.89 |
| HDL cholesterol | 1.21 (0.475–3.089), 0.72 | 15.551 (0.493–526.46), 0.10* |
| Glucose | 2.093 (1.204–3.639), 0.02 | 1.011 (0.109–9.369), 0.98 |
| 8-iso-PGF2α | 1.172 (1.064–1.290), 0.004 | 1.085 (0.712–1.653), 0.68 |
| PSS score | 1.135 (1.058–1.218), 0.001 | 1.056 (0.744–1.499), 0.72 |
Notes: Upper line – univariate model; lower line – multivariate model, adjusted for age, and current smoking. In regression models, hypertension was a dependent variable. *The atypical (95% CI) is owed to a small number of women.
Abbreviations: OR, odds ratio; CI, confidence interval; PSS, perceived stress scale; 8-iso-PGF2α, 8-iso-prostaglandin F2α.